Quick Answer
Akebia Therapeutics, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $236.20 million for the year ending 2025.
- Akebia Therapeutics, Inc. showed an increase of +47.5% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Akebia Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: $28.52 million | Q3 2017: $41.28 million | Q1 2018: $45.93 million | Q2 2018: $48.79 million | Q3 2018: $53.17 million | Q1 2019: $72.67 million | Q2 2019: $100.80 million | Q3 2019: $91.98 million | Q1 2020: $88.48 million | Q2 2020: $90.14 million | Q3 2020: $59.99 million | Q1 2021: $52.30 million | Q2 2021: $52.91 million | Q3 2021: $48.76 million | Q1 2022: $61.70 million | Q2 2022: $126.37 million | Q3 2022: $48.71 million | Q1 2023: $40.01 million | Q2 2023: $56.38 million | Q3 2023: $42.05 million | Q1 2024: $32.61 million | Q2 2024: $43.65 million | Q3 2024: $37.43 million | Q1 2025: $57.34 million | Q2 2025: $62.47 million | Q3 2025: $58.77 million.
- Over the full 10 years of available data (2016 to 2025), Akebia Therapeutics, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 15,287.4%.
- Historical annual values: Fiscal year 2025: $236.20 million | Fiscal year 2024: $160.18 million | Fiscal year 2023: $194.62 million | Fiscal year 2022: $292.48 million | Fiscal year 2021: $213.58 million | Fiscal year 2020: $295.31 million | Fiscal year 2019: $335.00 million | Fiscal year 2018: $207.74 million | Fiscal year 2017: $181.23 million | Fiscal year 2016: $1.54 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: